Profile data is unavailable for this security.
About the company
genedrive plc is a United Kingdom-based pharmacogenetic testing company. The Company is engaged in developing and commercializing a rapid, versatile, simple to use and robust point-of-need pharmacogenetic platform for the diagnosis of genetic variations. The Company’s products include Genedrive MT-RNR1 ID Kit, Genedrive System, and Genedrive CYP2C19 ID Kit. The Company’s flagship product Genedrive MT-RNR1 ID Kit is a single-use disposable cartridge that circumvents the requirement for cold chain logistics by providing temperature stable reagent test kits for use on their proprietary test platform. The Genedrive System is a rapid thermocycler and signal detection system, enabling PCR and isothermal based amplification techniques. It is a semi- automated system used for qualitative in vitro molecular diagnostic tests. Its Genedrive CYP2C19 ID Kit Molecular point-of-care test for rapid CYP2C19 genotyping in time-critical emergency care settings.
- Revenue in GBP (TTM)272.00k
- Net income in GBP-5.00m
- Incorporated2007
- Employees43.00
- LocationGenedrive PLC48 Grafton StreetMANCHESTER M13 9XXUnited KingdomGBR
- Phone+44 161 989 0245
- Fax+44 161 989 0262
- Websitehttp://www.genedriveplc.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myhealthchecked PLC | 9.39m | -1.04m | 6.50m | 10.00 | -- | 0.8627 | -- | 0.692 | -0.0201 | -0.0201 | 0.181 | 0.1449 | 1.03 | 5.17 | 26.92 | 939,400.00 | -11.41 | -7.24 | -12.91 | -10.39 | 7.92 | 22.82 | -11.06 | -5.13 | 11.58 | -- | 0.0016 | -- | -50.81 | 368.95 | -110.48 | -- | -2.00 | -- |
| Rua Life Sciences PLC | 2.19m | -1.44m | 6.67m | 33.00 | -- | 0.9289 | -- | 3.04 | -0.0551 | -0.0551 | 0.0653 | 0.1157 | 0.3168 | 4.30 | 3.91 | 66,393.94 | -20.82 | -24.63 | -22.39 | -26.81 | 81.06 | -- | -65.72 | -97.07 | 8.81 | -23.34 | 0.0514 | -- | 0.5507 | 36.46 | 28.11 | -- | 122.88 | -- |
| Genincode PLC | 2.60m | -5.94m | 7.34m | 36.00 | -- | 2.61 | -- | 2.83 | -0.0507 | -0.0507 | 0.0193 | 0.0159 | 0.4411 | 16.95 | 3.48 | 72,194.45 | -100.88 | -- | -127.83 | -- | 49.44 | -- | -228.70 | -- | 2.55 | -- | 0.0849 | -- | 51.05 | -- | -26.21 | -- | -- | -- |
| Cambridge Nutritional Sciences PLC | 9.77m | -328.00k | 7.61m | 94.00 | -- | 0.7865 | 23.65 | 0.779 | -0.0015 | -0.0015 | 0.0411 | 0.0407 | 0.6908 | 5.39 | 4.62 | 103,978.70 | -2.32 | -11.43 | -2.60 | -12.98 | 61.86 | 58.79 | -3.36 | -26.72 | 5.03 | -- | 0.0151 | -- | 29.53 | 2.22 | 89.66 | -- | -53.43 | -- |
| Proteome Sciences plc | 4.04m | -4.08m | 7.97m | 35.00 | -- | -- | -- | 1.98 | -0.0138 | -0.0138 | 0.0137 | -0.0178 | 0.3927 | 4.69 | 4.61 | 115,285.70 | -39.69 | -1.22 | -- | -- | 2.11 | 54.53 | -101.07 | -2.20 | 0.1388 | -3.70 | 1.63 | -- | -35.37 | 10.52 | -284.38 | -- | 126.22 | -- |
| Verici DX PLC | 3.35m | -3.72m | 8.23m | 19.00 | -- | 1.08 | -- | 2.45 | -0.0204 | -0.0204 | 0.0171 | 0.0315 | 0.4038 | -- | 5.71 | 239,531.30 | -44.82 | -- | -58.12 | -- | 77.06 | -- | -110.99 | -- | -- | -- | 0.0183 | -- | -- | -- | 23.43 | -- | -- | -- |
| Genedrive PLC | 272.00k | -5.00m | 12.08m | 43.00 | -- | 2.26 | -- | 44.43 | -0.0407 | -0.0407 | 0.0022 | 0.0098 | 0.0658 | -- | 1.60 | 6,325.58 | -120.84 | -97.55 | -197.86 | -128.51 | -- | -- | -1,837.50 | -797.03 | 1.36 | -7.49 | 0.0789 | -- | 12.24 | -50.95 | -10.16 | -- | 16.72 | -- |
| Abingdon Health PLC | 6.14m | -1.27m | 15.01m | 85.00 | -- | 4.37 | -- | 2.45 | -0.0104 | -0.0104 | 0.0484 | 0.0178 | 1.10 | 6.38 | 4.28 | 72,176.47 | -22.70 | -52.46 | -35.04 | -85.00 | 59.97 | 35.93 | -20.72 | -121.70 | 1.70 | -63.00 | 0.3181 | -- | 51.67 | 21.92 | 63.36 | -- | -15.69 | -- |
| Inspiration Healthcare Group PLC | 34.30m | -9.76m | 15.47m | 224.00 | -- | 0.5531 | -- | 0.4509 | -0.1421 | -0.1421 | 0.4985 | 0.3119 | 0.6557 | 1.54 | 4.11 | 153,120.50 | -18.66 | 1.04 | -22.64 | 1.28 | 44.88 | 47.61 | -28.46 | 1.16 | 1.15 | -1.75 | 0.3472 | -- | -8.74 | 19.43 | -2,318.38 | -- | 32.41 | -- |
| Belluscura PLC | 1.40m | -14.40m | 17.77m | 35.00 | -- | 1.17 | -- | 12.72 | -0.1003 | -0.1003 | 0.0095 | 0.0905 | 0.0742 | 0.3954 | 0.3956 | 39,911.57 | -76.44 | -49.84 | -84.73 | -54.78 | -33.28 | -66.07 | -1,030.73 | -1,277.34 | 2.09 | -10.15 | 0.00 | -- | -40.96 | 27.44 | -127.13 | -- | 41.32 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Peel Hunt LLPas of 24 Jun 2024 | 54.27m | 9.99% |
| Hargreaves Lansdown Asset Management Ltd.as of 01 Jan 2022 | 5.48m | 1.01% |
| Jarvis Investment Management Ltd.as of 14 Jun 2023 | 2.95m | 0.54% |
| IG Markets Ltd.as of 01 Jan 2022 | 2.74m | 0.50% |
| Rathbones Investment Management Ltd.as of 01 Jan 2022 | 2.35m | 0.43% |
| HSBC Global Asset Management (UK) Ltd.as of 01 Jan 2022 | 2.21m | 0.41% |
| BGF Investment Management Ltd.as of 05 Feb 2021 | 1.91m | 0.35% |
| Walker Crips Investment Management Ltd.as of 01 Jan 2022 | 1.90m | 0.35% |
| M&G Investment Management Ltd.as of 05 Feb 2020 | 1.76m | 0.32% |
| Unicorn Asset Management Ltd.as of 30 Sep 2024 | 1.15m | 0.21% |
